CytomX Therapeutics, Inc.

NASDAQ:CTMX

Biotechnology

Healthcare
$1.88 -0.91%

-$0.03 today

Market cap
$409.85M
Beta
2.09
P/E (TTM)
-8.8
EPS (TTM)
-$0.33
52W Low $1.72High $8.21

Volume 4.39M

Average 4.99M

Cash Flow

Check whether earnings turn into cash.

Operating Cash Flow

-$75.59M

FY 2025 · Annual

Investing Cash Flow

-$59.74M

FY 2025 · Annual

Financing Cash Flow

$110.45M

FY 2025 · Annual

+1368.3% YoY

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(83.61M)(99.32M)(569K)31.87M(17.37M)
Depreciation & Amortization2.71M5.86M2.18M1.77M1.38M
Deferred Income Tax272K0000
Stock-Based Compensation13.17M13.13M8.56M7.67M6.3M
Change in Working Capital(54.7M)(30.65M)(62.51M)(126.42M)(68.58M)
Accounts Receivables8K(35.2M)32.55M329K1.09M
Inventory11.64M0000
Accounts Payables(139K)68K(1.43M)(297K)221K
Other Working Capital(66.21M)4.47M(93.64M)(126.45M)(69.89M)
Other Non-Cash Items3.13M13.33M(3.69M)(1.12M)2.68M
Operating Cash Flow(119.03M)(110.79M)(56.04M)(86.23M)(75.59M)
Capital Expenditures(1.61M)(1.74M)(840K)(310K)(220K)
Acquisitions (Net)(24.1M)0000
Purchases of Investments(99.9M)0(424.83M)(155.49M)(192.52M)
Sales of Investments124M100M275M255.5M133M
Other Investing Activities24.1M0000
Investing Cash Flow22.49M98.26M(150.67M)99.7M(59.74M)
Debt Repayment00000
Common Stock Issued107.71M648K30.23M6.91M110.45M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities2.5M00613K0
Financing Cash Flow110.21M648K30.23M7.52M110.45M
Effect of Forex Changes00000
Net Change in Cash13.67M(11.88M)(176.48M)20.99M(24.89M)
Free Cash Flow(120.64M)(112.53M)(56.88M)(86.54M)(75.81M)

Free Cash Flow

Net Income to FCF bridge

FY2025

= Net Income-$17.4M
+ D&A$1.4M
+ Stock-Based Comp$6.3M
+ Deferred Tax$0
- Working Capital-$68.6M
+ Other Non-Cash$2.7M
= Operating Cash Flow-$75.6M
- Capex-$220.0K
= Free Cash Flow-$75.8M

Analysis

FY2025 free cash flow is -$75.8M. FCF conversion is 436.5% of net income. Operating cash flow was -$75.6M, with capex of -$220.0K. The largest bridge item is Working Capital at -$68.6M.

Recent Filings

Recent regulatory filings

FilingDescriptionDate
SC 13GSC 13G filingNov 10, 2026
8-KCurrent reportNov 5, 2026
10-QQuarterly reportNov 5, 2026
SC 13G/ASC 13G/A filingOct 28, 2026
4/A4/A filingOct 16, 2026

Does CTMX generate free cash flow?

CytomX Therapeutics, Inc. (CTMX) generated -$75.81M of free cash flow in fiscal 2025.

How much operating cash flow does CTMX produce?

Operating cash flow was -$75.59M, before capital expenditures of $220,000.00.